Skip to main content
. Author manuscript; available in PMC: 2012 Jul 11.
Published in final edited form as: Neurosci Lett. 2011 Jun 29;501(1):31–34. doi: 10.1016/j.neulet.2011.06.033

Fig. 2.

Fig. 2

RGS9-2 is a positive modulator of morphine analgesia in the tail immersion assay. RGS9KO mice showed decreased sensitivity to morphine in the tail immersion test, at low doses (1 mg/kg s.c.) compared to their RGS9WT controls (n = 11 per genotype). The thermal withdrawal latency is increased in wild-type but not in mutant mice. Both genotypes showed similar analgesic responses (n = 6–8) to morphine at higher doses (3 mg/kg). The analgesic effect of morphine in the tail immersion test is completely blocked following naloxone (NLX) administration (0.3 mg/kg s.c., n = 7–9 per group). Data are expressed as mean MPE ± SEM, *P < 0.05, two way ANOVA followed by Bonferroni post hoc test.